Skip to main content
. Author manuscript; available in PMC: 2011 Jul 29.
Published in final edited form as: Expert Opin Biol Ther. 2010 Jun;10(6):983–991. doi: 10.1517/14712598.2010.484801

Figure 1. Anti-p53 DC-based immunotherapy.

Figure 1

A. Replication null adenoviral particles containing the wild-type (wt)-p53 gene are transfected ex vivo into the patient autologous DCs (antigen presenting cells) to produce INGN-225 (Ad.p53-DC). B. p53 protein is synthesized and processed by the DCs. p53 peptides (epitopes) are expressed on the DC surface in the context of MHC I molecules. C. Naïve T cells recognize the p53 peptide on the surface of the antigen presenting cell (Ad.p53-DC/INGN-225) and are activated to proliferate and differentiate into effector T cells capable of recognizing and eliminating any p53 (over)expressing cell (malignant cells). D. Epithelial malignant cells (SCLC) with mutant (mu)-p53 gene and overexpressing p53 epitopes or TAAs are recognized and attacked by activated effector T cells. E. Cytokines (IL-2, INF-γ, granzymes) are produced, and malignant cells are destroyed.